Relmada Therapeutics (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants to investors, including Venrock Healthcare Capital Partners and Commodore Capital, to raise about $160 million. It expects to close the deal March 11.

Shares soared 46% as intraday trading volume surged to over 36.4 million from a daily average of about 676,000.

Dianthus Therapeutics (DNTH) said early Go decision was reached in phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy after 20 confirmed responders were achieved with less than 40 planned participants completing open-label part A of the trial. The firm also reported Q4 results.

Shares jumped 18% as intraday trading volume climbed to more than 3.2 million from a daily average of about 795,000.

Xenon Pharmaceuticals (XENE) reported "positive" topline results from its phase 3 study of azetukalner in focal onset seizures.

Shares soared 46% as intraday trading volume jumped to over 9.5 million from a daily average of roughly 917,000.

Price: 6.65, Change: +2.20, Percent Change: +49.33